FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Medicines Agency has waived the obligation to submit the results of studies with the reference product containing zoledronic acid in all subsets of the paediatric population in the treatment of tumour-induced hypercalcaemia and prevention of skeletal-related events in patients with advanced malignancies involving bone (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij referenčnega zdravila, ki vsebuje zoledronsko kislino za vse podskupine pediatrične populacije glede zdravljenja tumorsko povzročene hiperkalciemije in preprečevanja z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Zoledronic Acid Teva is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Slovenian: Zdravila Zoledronska kislina Teva ne priporočajo bolnikom, ki imajo že pred uvedbo zdravljenja težko ledvično okvaro, ki je za to skupino bolnikov opredeljena kot CLcr < 30 ml/min.
English: Each vial contains 5 ml of concentrate.
Slovenian: Ena viala vsebuje 5 ml koncentrata.
English: Table 2: Efficacy results (prostate cancer patients receiving hormonal therapy)
Slovenian: Preglednica 2: Rezultati učinkovitosti (bolniki z rakom prostate, ki so prejemali hormonsko zdravljenje)
English: 2031GA Haarlem The Netherlands
Slovenian: 2031GA Haarlem
English: The active substance in this medicine is zoledronic acid, which belongs to a group of substances called bisphosphonates.
Slovenian: Zdravilna učinkovina v zdravilu je zoledronska kislina, ki sodi v skupino snovi, ki se imenujejo difosfonati.
English: Zoledronic Acid Teva is supplied as packs containing 1, 4 or 10 vials.
Slovenian: Zdravilo Zoledronska kislina Teva je na voljo v pakiranju po 1, 4 ali 10 vial.
English: - Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.
Slovenian: - huda alergijska reakcija: zadihanost, otekanje zlasti v obraz in žrelo oziroma grlo.
English: Cyclic Olefin Polymer (COP) plastic vial or clear glass vial (type I) with chlorobutyl/butyl flurotec stopper and aluminium cap with plastic flip-off cap.
Slovenian: Plastična viala iz cikloolefinskega polimera (COP) ali prozorna steklena viala (tipa I) z zamaškom iz klorobutil/butil Flurotec in aluminijasto zaporko s plastično snemno zaporko.
English: After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10% of peak after 4 hours and < 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.
Slovenian: Po začetku infuzije zoledronske kisline so se plazemske koncentracije zoledronske kisline hitro zvišale, dosegle ob koncu obdobja infuzije vrh, ki mu je sledilo hitro znižanje na < 10 % najvišje koncentracije po 4 urah in na < 1 % najvišje koncentracije po 24 urah, čemur je sledilo dolgotrajno obdobje zelo nizkih koncentracij, ki pred drugo infuzijo zoledronske kisline na 28. dan niso presegle
English: Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent.
Slovenian: Pri posameznih in večkratnih 5-minutnih in 15-minutnih infuzijah 2, 4, 8 in 16 mg zoledronske kisline pri 64 bolnikih z zasevki v kosteh so dobili spodnje farmakokinetične podatke, za katere so ugotovili,
English: Each plastic or clear glass vial contains 5 ml of a clear, colourless concentrate.
Slovenian: Ena plastična ali prozorna steklena viala vsebuje 5 ml bistrega brezbarvnega koncentrata.
English: Teva Santé Tél: +33 1 55 91 7800
Slovenian: Tél: +33 1 55 91 7800
English: While being treated with Zoledronic Acid Teva, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
Slovenian: V času zdravljenja z zdravilom Zoledronska kislina Teva morate skrbeti za dobro ustno higieno (kar vključuje redno čiščenje zob) in redno hoditi na rutinske preglede k zobozdravniku.
English: The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06-0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose.
Slovenian: Varno območje, glede na učinke na ledvici, je bilo v dolgoročnih študijah večkratnih parenteralnih odmerkov na živalih ozko, vendar kumulativne koncentracije brez neželenih učinkov (NOAEL) pri enkratnih odmerkih (1,6 mg/kg) in pri do en mesec trajajočih študijah večkratnih odmerkov (0,06-0,6 mg/kg/dan) niso kazale na učinke na ledvici v odmerkih, ki so bili enakovredni največjemu nameravanemu človeškemu terapevtskemu odmerku ali ki so le-tega presegali.
English: Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½α 0.24 and t½β 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½γ 146 hours.
Slovenian: Intravensko dana zoledronska kislina se odstranjuje iz telesa s trifaznim procesom: hitro dvofazno izginotje iz sistemskega krvnega obtoka z razpolovnima časoma t½α 0,24 ure in t½β 1,87 ure, ki mu sledi dolga eliminacijska faza s terminalnim eliminacijskim razpolovnim časom t½γ 146 ur.
English: Proportion of patients with SREs (%) p-value
Slovenian: delež bolnic/bolnikov s SREs (%) vrednost p mediana časa do SRE
English: For instructions of the dilution of the medicinal product before administration, see section 6.6.
Slovenian: Za navodila glede redčenja zdravila pred dajanjem glejte poglavje 6.6.
English: - For single use only.
Slovenian: Samo za enkratno uporabo.
English: - if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth.
Slovenian: - če imate (ali ste imeli kdaj prej) bolečino, oteklino ali občutek odrevenelosti v čeljusti, če čutite težo v čeljusti ali se vam maje zob.
English: Following initiation of therapy, serum creatinine should be measured prior to each dose of Zoledronic Acid Teva and treatment should be withheld if renal function has deteriorated.
Slovenian: Po uvedbi terapije je treba izmeriti serumski kreatinin pred vsakim odmerkom zdravila Zoledronska kislina Teva, terapijo pa je treba prekiniti, če se je ledvična funkcija poslabšala.
English: Zoledronic Acid Teva treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Slovenian: Zdravljenje z zdravilom Zoledronska kislina Teva pri bolnikih s TIH, ki imajo tudi težko ledvično okvaro, lahko pride v poštev šele po oceni nevarnosti in koristnih učinkov zdravljenja.
English: The following conventional classification is used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Slovenian: Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
English: Please see below for maximum in-use storage time.
Slovenian: Za informacije najdaljšega shranjevanja pripravljene raztopine glejte spodaj.
English: Zoledronic acid Teva 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Slovenian: Zdravilo Zoledronska kislina Teva 4 mg/5 ml koncentrat za raztopino za infundiranje, nadaljnje razredčeno v 100 ml (glejte poglavje 6.6), je treba dajati v obliki ene same intravenske infuzije, ki traja najmanj 15 minut.
English: The other ingredients are: mannitol, sodium citrate and water for injections.
Slovenian: - Druge sestavine so: manitol, natrijev citrat in voda za injekcije.
English: Zoledronic acid was teratogenic in the rat at subcutaneous doses ≥ 0.2 mg/kg.
Slovenian: Zoledronska kislina je bila teratogena pri podganah pri subkutanih odmerkih ≥ 0,2 mg/kg.
English: In the zoledronic acid-treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1).
Slovenian: V skupini, zdravljeni z zoledronsko kislino, so opažali statistično značilno izboljšanje na bolečinski lestvici (uporabili so Brief Pain Inventory, BPI) po 4 tednih in ob vseh nadaljnjih časovnih točkah primerjave s placebom v študiji (slika 1).
English: The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the zoledronic acid -treated group versus 49.6% in the placebo group (p=0.003).
Slovenian: Delež bolnic z vsaj enim SRE (razen hiperkalciemije) je bil v skupini, zdravljeni z zoledronsko kislino 29,8 % v primerjavi s skupino s placebom, kjer je bil 49,6 % (p=0,003).
English: - The total time between dilution, storage in the refrigerator and end of administration must not exceed 24 hours.
Slovenian: - Celoten čas med razredčitvijo, shranjevanjem v hladilniku ter koncem infuzije ne sme presegati
English: The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.
Slovenian: Pričakuje se, da bodo zmanjšani odmerki pri bolnikih z ledvičnimi okvarami dosegli iste AUC, kot jih vidimo pri bolnikih z očistkom kreatinina
English: If the solution is not used immediately, storage prior to use is the responsibility of the user and should be in a refrigerator at 2°C - 8°C.
Slovenian: Če zdravstveni delavec raztopine ne uporabi takoj, je sam odgovoren za trajanje in pogoje shranjevanja pred uporabo, raztopina mora biti shranjena v hladilniku pri 2 °C - 8 °C.
English: − Osteonecrosis has also very rarely been seen occurring with other bones than the jaw, especially the hip or thigh.
Slovenian: − Osteonekrozo so zelo redko opažali tudi na drugih kosteh in ne le na čeljustnici, še posebej na kolku in stegnu.
English: In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ≥ 400 μmol/l or ≥ 4.5 mg/dl for patients with TIH and ≥ 265 μmol/l or ≥ 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of Zoledronic Acid Teva is not recommended in patients with severe renal impairment.
Slovenian: Glede na možni vpliv zoledronske kisline na delovanje ledvic ob pomanjkanju kliničnih podatkov o varnosti pri bolnikih s težko izhodiščno okvaro ledvic (v kliničnih preskušanjih opredeljeno s serumskim kreatininom ≥ 400 μmol/l ali ≥ 4,5 mg/dl za bolnike s tumorsko povzročeno hiperkalciemijo - TIH - oziroma s serumskim kreatininom ≥ 265 μmol/l ali ≥ 3,0 mg/dl za bolnike z rakom in zasevki v kosteh) in glede na samo omejene farmakokinetične podatke pri bolnikih s težko izhodiščno ledvično okvaro (očistek kreatinina < 30 ml/min), uporabe zdravila Zoledronska kislina Teva pri bolnikih s težko ledvično okvaro ne priporočamo.
English: - Low level of red blood cells (anaemia).
Slovenian: - nizka koncentracija rdečih krvnih celic (anemija), - konjuktivitis (vnetje očesne veznice).
English: When initiating treatment with Zoledronic Acid Teva in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined.
Slovenian: Pri uvajanju zdravljenja z zdravilom Zoledronska kislina Teva pri bolnikih z multiplim mielomom ali metastatičnimi kostnimi lezijami zaradi čvrstih tumorjev je treba določiti serumski kreatinin in očistek kreatinina (CLcr).
English: If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of Zoledronic acid Teva.
Slovenian: Če imate hipokalciemijo, jo je treba odpraviti preden prejmete prvi odmerek zdravila Zoledronska kislina Teva.
English: • To prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).
Slovenian: - preprečevanje zapletov na kosteh, na primer zlomov, pri odraslih bolnikih z metastazami v kosteh (z razširitvijo raka s prvotnega mesta na kosti),
English: 10 x 5 ml vials
Slovenian: 10 x 5 ml vial
English: - Since no data are available on the compatibility of zoledronic acid with other intravenously administered substances, zoledronic acid must not be mixed with other medicinal products/substances and should always be given through a separate infusion line.
Slovenian: - Ker o združljivosti zoledronske kisline z drugimi intravensko dajanimi snovmi ni na voljo nikakršnih podatkov, zoledronske kisline ne smete mešati z drugimi zdravili ali snovmi in jo moramo vedno dajati po ločenem infuzijskem sistemu.
English: - In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer medicinal products, anti-adhesion/invasion activity.
Slovenian: - In vitro: Inhibicijo proliferacije osteoblastov, neposredno citostatično in pro-apoptotično aktivnost pri tumorskih celicah, sinergističen citostatični učinek z drugimi zdravili proti raku,
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
Slovenian: Če ga uporabnik ne uporabi takoj, je sam odgovoren za čas in pogoje shranjevanja pred uporabo.
English: Placebo Δ Zoledronic acid 
Slovenian: Placebo Δ Zoledronska kislina 
English: Marketing Authorisation Holder Teva B.V.
Slovenian: Imetnik dovoljenja za promet Teva B.V.
English: For single use only.
Slovenian: samo za enkratno uporabo
English: Table 1 Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Slovenian: Neželeni učinki so razvrščeni glede na pogostnost, najprej najpogostejši, in to po naslednjem dogovoru: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
English: Zoledronic Acid Teva should not be used during pregnancy.
Slovenian: Zdravila Zoledronska kislina Teva ne smete uporabljati med nosečnostjo.
English: Hypocalcaemia is an important identified risk with Zoledronic Acid Teva in the approved indications.
Slovenian: Hipokalciemija predstavlja pomembno tveganje, ki ga opažajo pri uporabi zdravila Zoledronska kislina Teva za odobrene indikacije.
English: Teva B.V.
Slovenian: Teva Nederland B.V.
English: - Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely.
Slovenian: - redko se lahko pojavijo neobičajni zlomi stegnenice, še posebno pri bolnikih, ki so na dolgotrajnem zdravljenju osteoporoze.
English: Suomi/Finland rationpharm Oy Puh/Tel: +358 20 180 5900
Slovenian: Suomi/Finland ratiopharm Oy Puh/Tel: +358 20 180 5900
English: Prevention of skeletal related events in patients with advanced malignancies involving bone Adults and elderly people
Slovenian: Preprečevanje z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti Odrasli in starejši ljudje
English: Patients received either 4 mg zoledronic acid or placebo every four weeks for one year.
Slovenian: 4 mg zoledronske kisline bodisi placebo vsake štiri tedne.
English: Studies with glass bottles, as well as several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (prefilled with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution), showed no incompatibility.
Slovenian: Študije s steklenicami, več vrstami vreč za infundiranje in več vrstami infuzijskih sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena (predhodno napolnjenih z 9 mg/ml (0,9-odstotno) raztopino natrijevega klorida ali -odstotno m/v raztopino glukoze), niso pokazale nezdružljivosti.
English: What Zoledronic Acid Teva is and what it is used for What you need to know before you are given Zoledronic Acid Teva How Zoledronic Acid Teva is given Possible side effects
Slovenian: Kaj je zdravilo Zoledronska kislina Teva in za kaj ga uporabljamo Kaj morate vedeti, preden vam bodo dali zdravilo Zoledronska kislina Teva Kako se daje zdravilo Zoledronska kislina Teva
English: - The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line.
Slovenian: - Raztopino, ki vsebuje zoledronsko kislino, dajemo v obliki ene same 15-minutne intravenske infuzije z ločenim infuzijskim sistemom.
English: For storage condition after dilution of the medicinal product, see section 6.3.
Slovenian: Za pogoje shranjevanja po prvem odprtju zdravila glejte poglavje 6.3.
English: Zoledronic Acid Teva must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Slovenian: Zdravilo Zoledronska kislina Teva smejo predpisovati in dajati bolnikom samo zdravstveni delavci, ki imajo izkušnje z uporabo intravenskih difosfonatov.
English: Clinical studies in tumour-induced hypercalcaemia (TIH) demonstrated that the effect of zoledronic acid is characterised by decreases in serum calcium and urinary calcium excretion.
Slovenian: Rezultati kliničnih preskušanj v zdravljenju tumorsko povzročene hiperkalciemije (TIH) Klinične študije hiperkalciemije, povzročene s tumorjem (TIH), so pokazale, da je za učinek zoledronske kisline značilno znižanje serumskega kalcija in zmanjšanje izločanja kalcija z urinom.
English: What Zoledronic Acid Teva is and what it is used for
Slovenian: Kaj je zdravilo Zoledronska kislina Teva in za kaj ga uporabljamo
English: 4 x 5 ml vials
Slovenian: 4 x 5 ml viale
English: To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis.
Slovenian: Za oceno učinkov 4 mg zolendronske kisline v primerjavi s pamidronatom 90 mg so v vnaprej načrtovani analizi združili rezultate dveh ključnih multicentričnih študij pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH).
English: - Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs) - Flu-like symptoms including arthritis and joint swelling - Painful redness and/or swelling of the eye.
Slovenian: - intersticijska bolezen pljuč (vnetje tkiva okoli zračnih mešičkov v pljučih), - simptomi, ki spominjajo na gripo, vključno z artritisom in oteklinami sklepov, - boleča rdečina in/ali oteklina očesa.
English: How to prepare and administer Zoledronic Acid Teva - To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic Acid Teva concentrate (5 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution.
Slovenian: Kako pripraviti in dati bolniku zdravilo Zoledronska kislina Teva - Infuzijsko raztopino, ki vsebuje 4 mg zoledronske kisline, pripravite tako, da dodatno razredčite koncentrat zdravila Zoledronska kislina Teva (5 ml) s 100 ml infuzijske raztopine, ki ne vsebuje kalcija ali drugih dvovalentnih kationov.
English: Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with Zoledronic Acid Teva outweighs the possible risk.
Slovenian: Bolnike s tumorsko povzročeno hiperkalciemijo (TIH) in z znaki poslabšanja ledvične funkcije, moramo ustrezno ovrednotiti in pri tem pretehtati, ali možna korist zdravljenja z zdravilom Zoledronska kislina Teva odtehta možno nevarnost.
English: In the clinical trials, renal deterioration was defined as follows: - For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 μmol/l), an increase of
Slovenian: V kliničnih preskušanjih so opredelili ledvično poslabšanje takole: - pri bolnikih z normalnim izhodiščnim serumskim kreatininom (< 1,4 mg/dl ali < 124 μmol/l),
English: - Other medicines that also contain zoledronic acid and which are used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with Zoledronic Acid Teva are unknown.
Slovenian: - če se zdravite z zdravili, ki tudi vsebujejo zoledronsko kislino in se uporabljajo za zdravljenje osteoporoze in ostalih nerakavih bolezni kosti, ali če jemljete zdravila, ki vsebujejo katere koli druge difosfonate, saj skupni učinki jemanja teh zdravil skupaj z zdravilom Zoledronska kislina
English: - From a microbiological point of view, the diluted solution for infusion should be used immediately.
Slovenian: - Z mikrobiološkega stališča je razredčeno raztopino za infundiranje najbolje uporabiti takoj.
English: In patients who show evidence of renal deterioration during treatment, Zoledronic Acid Teva should be withheld.
Slovenian: Bolnikom, pri katerih se med zdravljenjem pokažejo znaki poslabšanja ledvične funkcije, je treba zdravilo Zoledronska kislina Teva ukiniti.
English: Zoledronic acid 8 mg (N=90)
Slovenian: zoledronska kislina 8 mg (N=90)
English: For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition.
Slovenian: Pri bolnikih, pri katerih se med difosfonatnim zdravljenjem razvije osteonekroza čeljustnic, lahko stomatološka operacija poslabša stanje.
English: The hydration status of patients must be assessed prior to and following administration of Zoledronic Acid Teva to ensure that they are adequately hydrated.
Slovenian: Status hidracije bolnikov mora zdravnik oceniti pred in po dajanju zdravila Zoledronska kislina Teva, da se prepriča, da so ustrezno hidrirani.
English: In clinical trials performed in patients with tumour-induced hypercalcaemia (TIH), the overall safety profile amongst all three treatment groups (zoledronic acid 4 and 8 mg and pamidronate 90 mg) was similar in types and severity.
Slovenian: V kliničnih preskušanjih pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH) je bil celotni varnostni profil v vseh treh zdravljenih skupinah (zoledronska kislina 4 in 8 mg in pamidronat 90 mg)
English: Day 10
Slovenian: 4. dan
English: LIST OF EXCIPIENTS Excipients: mannitol, sodium citrate and water for injections.
Slovenian: Pomožne snovi: manitol, natrijev citrat in voda za injekcije.
English: - Do not use Zoledronic Acid Teva after the expiry date stated on the vial and carton after EXP.
Slovenian: - Zdravila Zoledronska kislina Teva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in viali poleg oznake EXP.
English: Rare (may affect up to 1 in 1,000 people): - Slow heart beat.
Slovenian: Redki (pojavijo se lahko pri največ 1 do 1.000 bolnikov): - počasno bitje srca,
English: Intravenous use.
Slovenian: Način uporabe intravenska uporaba